- Approval Id
- d02bcf4b596c3c83
- Drug Name
- ANSTO - Sodium Iodide [131I] Therapy Capsules (50 to 6000 MBq)
- Product Name
- ANSTO - Sodium Iodide [131I] Therapy Capsules (50 to 6000 MBq)
- Approval Number
- SIN16117P
- Approval Date
- 2021-03-08
- Registrant
- TRANSMEDIC PTE LTD
- Licence Holder
- TRANSMEDIC PTE LTD
- Drug Type
- Therapeutic
- Forensic Classification
- Prescription Only
- Dosage Form
- CAPSULE
- Dosage
- **Dose and Administration**
The capsules are for oral administration and the dose ranges usually employed are as follows:
Thyrotoxicosis150–600 MBq
Thyroid ablation800–2000 MBq
Thyroid carcinoma2000–6000 MBq
(in two capsules)
- Route Of Administration
- ORAL
- Indication Info
- **Indications**
Sodium Iodide (131I) Therapy Capsules are indicated in the treatment of hyperthyroidism, and the detection and ablation of residual functioning thyroid tissue in differentiated thyroid carcinoma.
- Contraindications
- **Contraindications**
The use of this therapeutic radiopharmaceutical is absolutely contraindicated in women who are pregnant. Women of reproductive age should have a negative pregnancy test at the time of radionuclide therapy, and should take appropriate contraceptive measures.
The use of therapeutic iodine-131 is not recommended in persons with renal insufficiency, as delayed excretion will result in increased whole body radiation.
This therapy is contraindicated in-patients who are being treated concurrently with thyroid hormone or antithyroid drugs, are vomiting or have diarrhoea.
- **Note:** “Iodine allergy” is not a contraindication for use, because of the very small chemical amounts of iodine in therapy capsules (e.g. approx. 3 microgram in a 500 MBq capsule).
- Atc Code
- V10XA01
- Atc Item Name
- sodium iodide (131I)
- Pharma Manufacturer Name
- TRANSMEDIC PTE LTD
- Company Detail Path
- /organization/1296f2bee399ec5b/transmedic-pte-ltd
